Genentech, a unit of Roche Holding AG (RHHBY) Friday said the U.S. Food and Drug Administration or FDA has approved its Vabysmo prefilled syringe (PFS) to treat age-related macular degeneration (AMD) diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
Vabysmo PFS, which delivers the same medicine as the currently available Vabysmo vials, will be available in the coming months, the company said in a statement.
Vabysmo is currently approved in more than 95 countries for wet AMD and DME, and in several countries, including the U.S. and Japan, for RVO.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.